$ELV · Elevance Health, Inc.
Elevance Health EVP & CFO Mark Kaye reported the sale of 10,584 shares across 13 transactions at prices ranging from $434.00 to $447.19, generating total proceeds of $4,658,357. The sales were not executed under a 10b5-1 trading plan. Post-transaction, Kaye holds 19,919 shares.
- CFO Mark Kaye sold 10,584 shares for $4,658,357 total across 13 separate transactions.
- Sale prices ranged from $434.00 to $447.19 per share, executed in a single day.
- No 10b5-1 trading plan was indicated — sales were discretionary.
- Post-sale, Kaye retains 19,919 shares directly.
- The total disposed value represents a meaningful liquidity event for the CFO.
Markets closed — no regular-session reaction yet; extended-hours move not captured here. CFO sales without a 10b5-1 plan can draw scrutiny, though the dollar amount is modest relative to ELV's $95.41B market cap.
A CFO's discretionary $4.66M stock sale without a 10b5-1 plan raises questions about insider sentiment at a $95B managed-care giant.
_Not applicable._
Discretionary CFO sales without a 10b5-1 plan may signal reduced confidence in near-term outlook, though the retained stake of 19,919 shares partially mitigates this concern.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.